Objective: To investigate the correlation of serum interleukin 33（IL-33）and its receptor soluble suppression of tumorigenicity 2(sST2） with injury severity score(ISS) and prognosis in trauma patients. Methods: According to ISS, 67 trauma patients were divided into 2 groups, mild trauma group (ISS<20 points）and severe trauma group（ISS≥20 points）.Serum levels of IL-33, sST2 were measured at 4 h, 24 h, 72 h, 7 d after trauma, and mortality in 28 days were compared between mild trauma group and severe trauma group .Serum levels of IL- 33 and sST2 were compared between the survival and the dead patients. The receiver operating characteristic（ROC） curve was used to determine the cutoff value of indices for predicting the death of patient. Results: The levels of serum IL-33 and sST2 were significantly higher in severe trauma patients than those with mild trauma at 4 h and 24 h [IL-33, （38.75±28.43） pg/mL vs （19.62±9.98） pg/mL, （42.31±37.37） pg/mL vs （23.47±13.42） pg/mL, P<0.05; sST2,（6.50±3.74） ng/mL vs （4.89±2.40） ng/mL, （8.35±2.69） ng/mL vs （6.78±3.22） ng/mL, P<0.05]. The levels of serum IL-33 and sST2 were significantly higher in dead patients than in survival patients during 24 h-7d after trauma (P<0.01). The area under ROC curve of serum IL-33 and sST2 levels at 24 h after trauma were 0.799 (P=0.003) and 0.751( P=0.012), respectively. The optimal cutoff value of serum IL-33 and sST2 levels at 24 h after trauma were 15.27 pg/mL and 10.99 ng/mL respectively, and the sensitivity and specificity for predicting death were 100% and 70%,and 64% and 83%, respectively. Conclusions: Elevated levels of IL-33 and sST2 are associated with poor prognosis in patients with trauma, and serum IL-33 and sST2 at 24 h after trauma could be used as biomarkers for predicting prognosis in patients with trauma.
YAO Yulan, GUO Enwei, REN Dali, ZHANG Bingyu, YANG Feng, CHEN Qing, LIU Xinghui, LUO Qiancheng, FENG Gang
. Correlation of serum interleukin 33 and soluble suppression of tumorigenicity 2 with injury severity and prognosis in trauma patients[J]. Journal of Diagnostics Concepts & Practice, 2018
, 17(03)
: 299
-303
.
DOI: 10.16150/j.1671-2870.2018.03.013
[1] Søreide K. Epidemiology of major trauma[J]. Br J Surg, 2009 Jul,96(7):697-698.
[2] Manson J, Thiemermann C, Brohi K.Trauma alarmins as activators of damage-induced inflammation[J]. Br J Surg,2012,99(Suppl 1):12-20.
[3] Keel M, Trentz O.Pathophysiology of polytrauma[J]. Injury,2005,36(6):691-709.
[4] Cayrol C, Girard JP.IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy[J]. Curr Opin Immunol,2014,31:31-37.
[5] Gadani SP, Walsh JT, Smirnov I, et al.The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury[J]. Neuron,2015,85(4):703-709.
[6] 冯刚, 陈庆, 郭恩伟, 等. 创伤患者血清IL-33和sST2的变化及意义[J]. 中国急救医学,2016,36(10):904-907.
[7] Mildner M, Storka A, Lichtenauer M, et al.Primary sources and immunological prerequisites for sST2 secretion in humans[J]. Cardiovasc Res,2010,87(4):769-777.
[8] Weinberg EO, Shimpo M, De Keulenaer GW, et al.Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction[J]. Circulation,2002,106(23):2961-2966.
[9] Nagata A, Takezako N, Tamemoto H, et al.Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells[J]. Cell Mol Immunol,2012,9(5):399-409.
[10] Takezako N, Hayakawa M, Hayakawa H, et al.ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells[J]. Biochem Biophys Res Commun,2006,341(2):425-432.
[11] Gao S, Huan SL, Han LY, et al.Overexpression of serum sST2 is associated with poor prognosis in acute-on-chronic hepatitis B liver failure[J]. Clin Res Hepatol Gastroenterol,2015,39(3):315-323.
[12] Bao YS, Na SP, Zhang P, et al.Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease[J]. J Clin Immunol,2012,32(3):587-594.
[13] Coglianese EE, Larson MG, Vasan RS, et al.Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study[J]. Clin Chem,2012,58(12):1673-1681.
[14] Miller AM, Purves D, McConnachie A, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?[J]. PLoS One,2012,7(10):e47830.
[15] Caporali A, Meloni M, Miller AM, et al.Soluble ST2 is regulated by p75 neurotrophin receptor and predicts mortality in diabetic patients with critical limb ischemia[J]. Arterioscler Thromb Vasc Biol,2012,32(12):e149-e160.
[16] Zhang K, Zhang XC, Mi YH, et al.Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction[J]. Chin Med J (Engl),2013,126(19):3628-3631.
[17] Bergis D, Kassis V, Ranglack A, et al.High Serum Leve-ls of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma[J]. Transl Oncol,2013,6(3):311-318.
[18] Dieplinger B, Mueller T.Soluble ST2 in heart failure[J]. Clin Chim Acta,2015,443:57-70.
[19] Chen LQ, de Lemos JA, Das SR, et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study[J]. Clin Chem,2013,59(3):536-546.
[20] Xu J, Guardado J, Hoffman R, et al.IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model[J]. PLoS Med,2017,14(7):e1002365.
